Amgen Wins Round in Battle to Keep Roche’s EPO Off Market
Executive Summary
Amgen has the edge as its patent battle against Roche goes to trial this week since the federal judge overseeing the dispute found that Roche's anti-anemia drug Mircera infringes a key Amgen patent
You may also be interested in...
“World Series” Trial: Verdict Against Mircera Gives Amgen ESA Market Hold
While Roche is considering whether to appeal a jury verdict that its anti-anemia drug Mircera infringes Amgen's erythropoietin patents covering Epogen and Aranesp, Amgen is likely to retain its dominance over the $6 billion-plus erythropoiesis-stimulating agents market for some time
“World Series” Trial: Verdict Against Mircera Gives Amgen ESA Market Hold
While Roche is considering whether to appeal a jury verdict that its anti-anemia drug Mircera infringes Amgen's erythropoietin patents covering Epogen and Aranesp, Amgen is likely to retain its dominance over the $6 billion-plus erythropoiesis-stimulating agents market for some time
Roche Puts “Mind Towards” Phase III For CETP Inhibitor
Roche is leaning in favor of initiating a Phase III study of its cholesteryl ester transfer protein inhibitor, R1658, after conducting an in-depth analysis of data, evaluating information on Pfizer's failed torcetrapib and consulting experts